NFX vs. CIZ, TCF, GENF, EVG, MTFB, BSFA, DEST, VAL, ROQ, and RENE
Should you be buying Nuformix stock or one of its competitors? The main competitors of Nuformix include Cizzle Biotechnology (CIZ), Theracryf (TCF), Genflow Biosciences (GENF), Evgen Pharma (EVG), Motif Bio (MTFB), BSF Enterprise (BSFA), Destiny Pharma (DEST), ValiRx (VAL), Roquefort Therapeutics (ROQ), and ReNeuron Group (RENE). These companies are all part of the "biotechnology" industry.
Nuformix vs. Its Competitors
Nuformix (LON:NFX) and Cizzle Biotechnology (LON:CIZ) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations.
Cizzle Biotechnology is trading at a lower price-to-earnings ratio than Nuformix, indicating that it is currently the more affordable of the two stocks.
In the previous week, Nuformix's average media sentiment score of 0.00 equaled Cizzle Biotechnology'saverage media sentiment score.
Nuformix has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500. Comparatively, Cizzle Biotechnology has a beta of 0.38, suggesting that its share price is 62% less volatile than the S&P 500.
Cizzle Biotechnology's return on equity of -0.23% beat Nuformix's return on equity.
0.1% of Nuformix shares are owned by institutional investors. Comparatively, 0.0% of Cizzle Biotechnology shares are owned by institutional investors. 11.2% of Nuformix shares are owned by insiders. Comparatively, 72.2% of Cizzle Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Nuformix currently has a consensus price target of GBX 293, indicating a potential upside of 261,507.14%. Given Nuformix's stronger consensus rating and higher possible upside, equities research analysts plainly believe Nuformix is more favorable than Cizzle Biotechnology.
Summary
Nuformix beats Cizzle Biotechnology on 8 of the 11 factors compared between the two stocks.
Get Nuformix News Delivered to You Automatically
Sign up to receive the latest news and ratings for NFX and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nuformix Competitors List
Related Companies and Tools
This page (LON:NFX) was last updated on 9/13/2025 by MarketBeat.com Staff
Free NFX Stock Alerts